相关实验视频
Updated: Mar 25, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
管理肥胖症
George A Bray1, Gema Frühbeck2, Donna H Ryan1
1Pennington Biomedical Research Center/LSU, Baton Rouge, LA, USA.
Lancet (London, England)
|February 13, 2016
概括
有效的肥胖管理需要改变饮食和运动等生活方式. 对于一些人来说,药物治疗或减肥手术可能是必要的,以实现显著的减肥和改善健康结果.
科学领域:
- 肥胖药物
- 代谢健康
- 减肥科学
背景情况:
- 肥胖是一种复杂的疾病,
- 减肥对健康有很大的好处,
- 生活方式干预是减肥策略的基石.
研究的目的:
- 概述一种全面,现代的肥胖管理方法.
- 详细介绍成功减肥生活方式的组成部分.
- 对那些在控制体重方面有困难的人进行药物和手术的选择进行审查.
主要方法:
- 强调高质量,可持续的饮食变化.
- 详细说明运动的频率,强度,类型和持续时间 (每周至少150分钟的适度活动).
- 考虑药物管理和批准的体重控制药物.
- 对严重肥胖的手术进行评估.
主要成果:
- 包括饮食和运动在内的生活方式改变是减肥的基础.
- 药物辅助减肥和手术可以显著改善健康状况.
- 已批准的药物包括奥利斯塔特,纳尔特雷/布普罗和利拉格卢提德.
- 胃带术,袖子胃切除术和Roux-en Y胃绕道术等手术可以减少严重肥胖患者的死亡率.
结论:
- 综合生活方式,药物和手术的多因素方法对于有效的肥胖治疗至关重要.
- 个性化策略是实现持续减肥和改善患者健康的关键.
- 现代肥胖症的治疗方法承认其复杂性, 并提供多种治疗方案.
相关概念视频
Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
368
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
Drug Dosing: Obese Patients
335
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
335
Atherosclerosis III: Management
577
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
279
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
279

